Ligand Pharmaceuticals (LGND) Profit After Tax (2010 - 2026)

Ligand Pharmaceuticals has disclosed Profit After Tax across 17 years of filings, most recently posting -$13.3 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$13.3 million, up 68.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $153.6 million (up 215.79% YoY), and the FY2025 annual result was $124.5 million, up 3186.63% from the prior year.
• Profit After Tax came in at -$13.3 million for Q1 2026 at Ligand Pharmaceuticals, down from $44.8 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $117.3 million in Q3 2025 to a low of -$51.9 million in Q2 2024.
• The 5-year median for Profit After Tax is -$895000.0 (2022), against an average of $7.5 million.
• Across the five-year window, Profit After Tax tumbled 2642.82% in 2023 and jumped 1735.15% in 2025, its largest moves.
• Ligand Pharmaceuticals' Profit After Tax stood at -$17.5 million in 2022, then soared by 213.54% to $19.9 million in 2023, then tumbled by 256.59% to -$31.1 million in 2024, then soared by 244.06% to $44.8 million in 2025, then tumbled by 129.8% to -$13.3 million in 2026.
• The last three Profit After Tax figures came in at -$13.3 million (Q1 2026), $44.8 million (Q4 2025), and $117.3 million (Q3 2025), per Business Quant data.